Researchers from the Accelerating Medicines Partnership SLE Consortium reported phase 2 results during a Sunday morning session.

During Sunday morning’s Plenary II session, researchers reported results from the VITAL trial, ORAL Surveillance, and STOP-JIA, among others.

In Sunday’s Oscar S. Gluck, MD Memorial Lecture, Marc Hochberg, MD, MPH, described research into the pathogenesis and progression of OA that has helped identify new targets for therapeutic intervention.

Musculoskeletal conditions, particularly rheumatic diseases like RA and lupus, are among the most common causes of employment problems, according to Edward H. Yelin, PhD, who delivered Sunday’s ARP Distinguished Lecture.

The FDA has been busy during the COVID-19 pandemic, with emergency use authorizations for two rheumatology agents, approvals for new agents, and new indications and safety warnings for both prescription and OTC medications.

During a Monday session, Amanda Crawford, CRNP, CCD, and Saba Mohiuddin, PharmD, BCACP, discussed the management of osteoporosis, with a special focus on diagnostic imaging and pharmaceutical interventions.